Rhenman & Partners Asset Management AB Grows Stake in Natera, Inc. $NTRA

Rhenman & Partners Asset Management AB grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 30.6% during the fourth quarter, HoldingsChannel reports. The fund owned 40,500 shares of the medical research company’s stock after purchasing an additional 9,500 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Natera were worth $9,278,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Horizon Investments LLC lifted its position in Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after acquiring an additional 44 shares during the period. Sound Income Strategies LLC lifted its position in Natera by 20.0% during the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock worth $62,000 after acquiring an additional 45 shares during the period. Savvy Advisors Inc. lifted its position in Natera by 3.1% during the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock worth $353,000 after acquiring an additional 46 shares during the period. Siemens Fonds Invest GmbH lifted its position in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the period. Finally, First Horizon Corp lifted its position in Natera by 7.3% during the 4th quarter. First Horizon Corp now owns 931 shares of the medical research company’s stock worth $213,000 after acquiring an additional 63 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Piper Sandler reissued an “overweight” rating and issued a $249.00 price target on shares of Natera in a report on Tuesday, May 12th. Robert W. Baird set a $265.00 price target on Natera in a report on Friday, May 8th. Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price target for the company. Royal Bank Of Canada initiated coverage on Natera in a report on Thursday. They issued an “outperform” rating and a $275.00 price target for the company. Finally, Evercore reissued an “outperform” rating and issued a $270.00 price target on shares of Natera in a report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $256.53.

Insider Activity

In related news, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director directly owned 6,183 shares of the company’s stock, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $193.74, for a total value of $594,781.80. Following the transaction, the chief financial officer directly owned 58,291 shares of the company’s stock, valued at approximately $11,293,298.34. This represents a 5.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 159,378 shares of company stock valued at $34,640,860 in the last 90 days. Insiders own 5.05% of the company’s stock.

Natera Price Performance

NTRA opened at $212.07 on Friday. The business has a 50 day simple moving average of $206.49 and a 200-day simple moving average of $215.99. The stock has a market capitalization of $30.37 billion, a P/E ratio of -130.10 and a beta of 1.56. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $256.36.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.